

REMARKS

Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 231, 233-235, 237, 238, 240, 242, 245-252, 254, and 256-264 were pending in the present application. Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 231, 233-235, 237, 238, 240, 242, 245-251, 254, and 256-264 have been canceled and claims 265-277 have been added. Applicants thank the Examiner for allowing claims 231 and 252 upon condition that claim 231 be re-written as an independent claim. Claim 265 corresponds to claim 231 in a re-written format, wherein the SEQ ID NO of each CDR has been incorporated as an alternative to the ATCC deposit, and claims 266-277 depend from this claim. The remarks made herein are designed to place the case in condition for allowance. As such, Applicants respectfully request that the remarks made herein be entered and fully considered.

Objections

The specification was objected to because “09/345,068” on page 3, line 3 should have been “09/345,468”. Applicants note that this typo is actually on page 1 of the specification. Additionally, the Examiner asserts that the title of the invention is not descriptive and suggests changing the title to “Glycoprotein VI antibodies and uses thereof”. Applicants submit herewith an amendment to correct the typo on page 1 and Applicants have changed the title as suggested by the Examiner.

I. Rejection of Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251 and 256-264 Under 35 U.S.C. § 112, ¶1

Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251 and 256-264 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors, at the time the application was filed, had possession of the claimed invention.

Applicants have cancelled all of the above mentioned claims in favor of new claims 265 to 277. As claim 265 corresponds to allowable claim 231 written as an independent claim, the foregoing 35 U.S.C. § 112, first paragraph rejection over claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251 and 256-264 is moot. Therefore, Applicants respectfully request reconsideration and withdrawal of the foregoing 35 U.S.C. § 112, first paragraph rejection.

II. Rejection of Claims 247 and 249-251 Under 35 U.S.C. § 112, ¶1

Claims 247 and 249-251 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the art that the inventors, at the time the application was filed, had possession of the claimed invention. This is a new matter rejection.

Applicants have cancelled claims 247 and 249-251, thereby rendering the foregoing 35 U.S.C. § 112, first paragraph rejection over claims 247 and 249-251 moot. Therefore, Applicants respectfully request reconsideration and withdrawal of the foregoing 35 U.S.C. § 112, first paragraph rejection.

III. Rejection of Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251, 254 and 256-264 Under 35 U.S.C. § 112, ¶2

Claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251, 254 and 256-264 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Applicants have cancelled claims 132-136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 155, 157, 159, 161-165, 168, 169, 171, 173, 175-178, 180, 181, 183, 185, 187-189, 191, 192, 194, 196, 198-201, 203, 205, 207, 208, 210-213, 215, 216, 218, 220, 222-224, 226, 227, 229, 233-235, 237, 238, 240, 242, 245-251, 254 and 256-264, thereby rendering the foregoing 35 U.S.C. § 112, second paragraph rejection moot. Therefore, Applicants respectfully request reconsideration and withdrawal of the foregoing 35 U.S.C. § 112, second paragraph rejection.

IV. Rejection of Claim 254 Under 35 U.S.C. § 102(b)

Claim 254 is rejected under 35 U.S.C. § 102(b), as being anticipated by Sugiyama et al. (Blood 69(6):1712-1720) and Gibbins et al (FEBS Letters 413:255-259, 1997).

Applicants have cancelled claim 254, thereby rendering the foregoing 35 U.S.C. § 102(b) rejection over claim 254 moot. Therefore, Applicants respectfully request reconsideration and withdrawal of the foregoing 35 U.S.C. § 102(b) rejection.

CONCLUSION

In view of the amendments and remarks made herein, Applicants respectfully submit that the objections and rejections presented by the Examiner are now overcome and that this application is now in condition for allowance. Early notice to this effect is solicited.

If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned.

It is believed that this paper is being filed timely and that a three month extension of time is required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

<u>May 18, 2004</u>	MILLENNIUM PHARMACEUTICALS, INC. By  Jean M. Silveri Registration No. 39,030 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-679-7336 Facsimile - 617-551-8820
---------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------